John Kent Lin

John Kent Lin

Auto-generated profile, based on publicly available information

John Kent Lin

University of Texas MD Anderson Cancer Center, Houston, TX

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2014
Verified
Conference Paper
Open access
VVVeer N. Vatsa
Veer N. Vatsa
DCDamiano Casalino
Damiano Casalino
JLJohn C. Lin
John C. Lin
JAJason Appelbaum
Jason Appelbaum

3 June 2022 in JAMA Health Forum
Verified
Journal Article
Open access
PDF file
JLJohn K. Lin
John K. Lin
PLPengxiang Li
Pengxiang Li
JDJalpa A. Doshi
Jalpa A. Doshi
SDSunita M. Desai
Sunita M. Desai
The federal 340B Drug Pricing Program entitles participating health care institutions to contract with pharmacies to dispense drugs purchased at discount to their patients. Previously, 340B institutions could contract with only a single pharmacy. In part responding to concerns about patient access in socioeconomically disadvantaged communities,1 starting in 2010, 340B institutions could contract with an unlimited number of pharmacies. In this study of annual cross-sections, we measured pharmacy participation following the 2010 expansion and the extent to which growth has occurred in socioeconomically disadvantaged neighborhoods.

1 November 2020 in Journal of Surgical Education
Verified
Journal Article
Closed access
JLJohn C Lin
John C Lin
APAlfred A Paul
Alfred A Paul
PGPaul B Greenberg
Paul B Greenberg

18 January 2022 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
PDF file
ASAlexander T. Sandhu
Alexander T. Sandhu
PHPaul Heidenreich
Paul Heidenreich
JLJohn Lin
John Lin
JPJustin Parizo
Justin Parizo
JBJay Bhattacharya
Jay Bhattacharya
JGJeremy D. Goldhaber-Fiebert
Jeremy D. Goldhaber-Fiebert
Background: Rising drug costs have increased interest in performance-linked reimbursement (PLR) contracts that tie payment to patient outcomes. PLR is theoretically attractive to payers interested in reducing the risk of overpaying for expensive drugs, to manufacturers working to improve early drug adoption, and to patients seeking improved access. Multiple PLR contracts were developed for sacubitril-valsartan. We evaluated how the characteristics of a PLR contract influence its performance. Methods: We used a published cost-effectiveness model of sacubitril-valsartan. We evaluated hypothetical PLR contracts that adjusted drug payment based on observed therapy effectiveness. Ideally, these contracts reduce the uncertainty around the value obtained with purchasing sacubitril-valsartan. By reducing the financial risk in covering an ineffective therapy, PLR incentivizes insurers to increase patient access. We measured the uncertainty in value as the SD of the incremental net monetary benefit (INMB), an estimate of therapy value incorporating costs and clinical benefits. We evaluated the change in INMB SD under a variety of different assumptions regarding contract design, therapy effectiveness, and population characteristics. Results: Over 2 years, sacubitril-valsartan led to 0.042 additional quality-adjusted life-years at an incremental cost of $4916. Using a willingness-to-pay of $150 000 per quality-adjusted life-year, this led to a mean INMB across simulations of $1416 (SD, $1720). A PLR contract that adjusted payment based on cardiovascular mortality reduced the INMB SD moderately by 20.7% while a contract based on all-cause mortality was more effective (INMB SD reduction of 27.3%). A contract based on heart failure hospitalization reduction was ineffective. PLR effectiveness increased with greater uncertainty regarding therapy effectiveness or in sicker cohorts (eg, New York Heart Association Class III/IV heart failure). Contracts required precise estimates of treatment effect in addition to trust or verifiability between manufacturers and payers concerning patient selection. Conclusions: The development of accurate prospective estimates of treatment effectiveness using actual enrollee characteristics will be critical for successful PLR. If able to meet these requirements, PLRs could incentivize insurers to expand access to expensive treatments by reducing financial risk.

19 August 2021 in Seminars in Ophthalmology
Verified
Journal Article
Closed access
JLJohn C Lin
John C Lin
ALAnagha Lokhande
Anagha Lokhande
ISIngrid U Scott
Ingrid U Scott
PGPaul B Greenberg
Paul B Greenberg
To investigate the characteristics of first-year ophthalmology residents associated with high research productivity in twelve years.All first-year ophthalmology residents in the United States (US) ...

1 April 2024 in Journal of Graduate Medical Education
Verified
Journal Article
Open access
PDF file
JLJohn C. Lin
John C. Lin
DHDaniel J. Hu
Daniel J. Hu
ISIngrid U. Scott
Ingrid U. Scott
PGPaul B. Greenberg
Paul B. Greenberg
Background Although the selection interview is a standard admission practice for graduate medical education (GME) programs in the United States, there is a dearth of recent reviews on optimizing the trainee interview process, which has low reliability, high cost, and major risk of bias. Objective To investigate the evidence base for different selection interview practices in GME. Methods We searched 4 literature databases from inception through September 2022. Two investigators independently conducted title/abstract screening, full-text review, data extraction, and quality assessment. Disagreements were mediated by discussion. We used backward reference searching of included articles to identify additional studies. We included studies of different interview methods and excluded literature reviews, non-GME related publications, and studies comparing different applicant populations. We examined study characteristics, applicant and interviewer preferences, and interview format. We evaluated study quality using the Medical Education Research Study Quality Instrument (MERSQI). Results Of 2192 studies, 39 (2%) met our inclusion criteria. The evidence base was rated as moderately low quality using MERSQI criteria. Applicants reported preferences for several one-on-one interviews lasting 15 to 20 minutes, interviews by current trainees, and interviews including social events with only trainees. Applicants had mixed perceptions of virtual versus in-person interviews and reported that virtual interviews saved costs. The multiple mini interview (MMI) required more applicant and interviewer time than individual interviews but demonstrated construct and predictive validity and was preferred by applicants and interviewers. Conclusions Based on moderately low-quality evidence, using the MMI, training interviewers, and providing applicants with basic program information in advance should be considered for GME selection interviews.